辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作

智通财经10-15

智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出："在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

庄棋铭
10-15
庄棋铭
还有眼光和见识的CEO。

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2575513203?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-15 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575513203","market":"hk","top_or_hot":-1,"title":"辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1355242.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 15:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1355242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1355242.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1355242.html","article_id":"2575513203","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575513203","pubTimestamp":1760511620,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，辉瑞首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","BK4550":"红杉资本持仓","BK4592":"伊斯兰概念","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","BK4599":"减肥药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","PFE":"辉瑞","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC"},"translate_title":"Pfizer (PFE.US) CEO Calls: US Pharmaceutical Industry Needs to Cooperate with China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.5},"content_text":"智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对数百亿美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，中国生物制药企业招募临床试验患者的效率可达美国同行的2至5倍。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":489477155615168,"gmtCreate":1760528839503,"gmtModify":1760528841706,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","vip":1,"hat":"https://static.tigerbbs.com/e6295840391b9cdc17115677ba51429c","crmLevel":8,"crmLevelSwitch":0,"authorIdStr":"3447258680782140","idStr":"3447258680782140"},"htmlText":"还有眼光和见识的CEO。","listText":"还有眼光和见识的CEO。","text":"还有眼光和见识的CEO。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/489477155615168","repostId":2575513203,"repostType":2,"repost":{"id":"2575513203","kind":"news","pubTimestamp":1760511620,"share":"https://www.laohu8.com/m/news/2575513203?lang=&edition=full","pubTime":"2025-10-15 15:00","market":"hk","language":"zh","title":"辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2575513203","media":"智通财经","summary":"智通财经APP获悉，辉瑞首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。</p><p>布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。</p><p>此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对<a href=\"https://laohu8.com/S/SBAY\">数百亿</a>美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。</p><p>美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。</p><p>尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国<a href=\"https://laohu8.com/S/01530\">三生制药</a>达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。</p><p>布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>企业招募临床试验患者的效率可达美国同行的2至5倍。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 15:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1355242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1355242.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","BK4550":"红杉资本持仓","BK4592":"伊斯兰概念","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","BK4599":"减肥药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","PFE":"辉瑞","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1355242.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2575513203","content_text":"智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对数百亿美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，中国生物制药企业招募临床试验患者的效率可达美国同行的2至5倍。","news_type":1,"symbols_score_info":{"PFE":1.5}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":2,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575513203","isCrawlerRequest":true}